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Abstract
To evaluate recent improvements in lung cancer screening, we compared the results of re-
cently conducted lung cancer screening with those of a previous screening. This study compared
the survival of lung cancer patients detected by lung cancer screening conducted between 1976
and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred
seventy-six patients with lung cancer were detected in the early period and 541 patients with lung
cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8
months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer
detected in the late period were significantly better than those in the early period (p = 0.0054).
Among patients undergoing resection, the proportion of pathological stage I patients in the late
period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p =
0.005). Multivariate analysis showed that the screening time period was a significant prognostic
factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results
were consistent with the findings of case-control studies of lung cancer screening programs in the
late period recently conducted in Japan, which also showed a greater efficacy for screening than
for previous case-control studies in the early period.
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urrently,  lung cancer is the leading cause of 
cancer-related death in Japan,  with 50,871 
patients dying of lung cancer in 1998 [1].  In an 
attempt to reduce lung cancer mortality,  lung cancer 
screening with chest x-ray and sputum cytology uti-
lizing the screening system developed for pulmonary 
tuberculosis were performed in Japan until 1986. 
Since 1987,  the Japanese government,  on the basis 
of the Health and Medical Services Law for the 
Aged,  has supported lung cancer screening. 
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To evaluate recent improvements in lung cancer screening,  we compared the results of recently 
conducted lung cancer screening with those of a previous screening.  This study compared the sur-
vival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 
(early period) with that conducted between 1989 and 1997 (late period).  Two hundred seventy-six 
patients with lung cancer were detected in the early period and 541 patients with lung cancer were 
detected in the late period.  The median survival time (late : 49.8 vs.  early : 27.8 months) and the 
5-year survival rate (late : 47.8 vs.  early : 34.8ｵ) of the patients with lung cancer detected in the late 
period were signiﬁ cantly better than those in the early period (p ＝ 0.0054).  Among patients undergo-
ing resection,  the proportion of pathological stage I patients in the late period was signiﬁ cantly 
higher than that in the early period (late : 60.8 vs.  early : 54.9ｵ,  p ＝ 0.005).  Multivariate analysis 
showed that the screening time period was a signiﬁ cant prognostic factor (hazard ratio ＝ 0.685,  95ｵ 
conﬁ dence interval : 0.563ﾝ0.832,  p ＝ 0.0002).  These results were consistent with the ﬁ ndings of case-
control studies of lung cancer screening programs in the late period recently conducted in Japan, 
which also showed a greater eﬃ  cacy for screening than for previous case-control studies in the 
early period.
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However,  to date,  the eﬀ ectiveness of lung cancer 
screening has not been established.  In the USA,  the 
eﬀ ectiveness of lung cancer screening was assessed 
in randomized trials sponsored by the National 
Cancer Institute (NCI) conducted at Johns Hopkins 
University [2],  Memorial Sloan-Kettering Cancer 
Center [3],  and the Mayo Clinic [4] in the 1970s. 
Although these trials demonstrated that the resect-
ability and survival of lung cancer patients in the 
screening group were superior compared with those 
in the control group,  no reduction in overall lung 
cancer mortality was shown.  These results were 
thought to be due to lead-time bias or over-diagnosis 
bias [5,  6].  Based on these ﬁ ndings,  the U.S. 
Preventive Services Task Force declared that rou-
tine screening for lung cancer with chest radiography 
or sputum cytology in asymptomatic persons was not 
recommended (U.S.  Preventive Services Task Force 
home page 〈http : //www.ahcpr.gov/clinic/uspstf/
uspslung.htm〉,  accessed on Oct 17,  2005).
　　On the other hand,  Sobue et al.  in Japan evalu-
ated the eﬀ ectiveness of the annual chest x-ray sys-
tem developed for pulmonary tuberculosis screening 
conducted between 1977 and 1987.  Using a case-con-
trol design,  they showed a reduction of lung cancer 
mortality by a maximum of 28ｵ (odds ratio : 0.72, 
95ｵ conﬁ dence interval : 0.50ﾝ1.03).  Their data 
included part of the screening results conducted in 
the Okayama prefecture.  However,  their results 
were not statistically signiﬁ cant (p ＝ 0.07) [7].  In 
1998,  4 case-control studies ̶ including our study 
[8],  supported by the Ministry of Health and 
Welfare ̶ were planned in Japan to evaluate the 
eﬀ ectiveness of the new lung cancer screening pro-
gram supported by the government under the Health 
and Medical Services Law for the Aged [8ﾝ11].  Our 
study evaluated 412 patients who died of lung cancer 
between 1991 and 1996 in the Okayama prefecture 
and showed that lung cancer screening signiﬁ cantly 
reduced lung cancer mortality by 41ｵ (smoking-
adjusted odds ratio ＝ 0.59 ; 95ｵ conﬁ dence inter-
val : 0.46ﾝ0.74 ; p ＝ 0.0001) [8].  Furthermore,  2 
other studies also showed a signiﬁ cant reduction of 
lung cancer mortality as a result of screening [9, 
10].  In order to elucidate why the recent lung cancer 
screening reduced lung cancer mortality while previ-
ous studies had shown negative results,  we designed 
a comparison of the data gathered from the recent 
lung cancer screening with the older screening data.
Materials and Methods
　　This study compared the results of lung cancer 
screening conducted between 1976 and 1984 (early 
period),  which were used in the Sobue study [7], 
with those gathered between 1989 and 1997 (late 
period),  which were used in the Nishii study [8]. 
The study area of the 2 cohorts was the same 
(Okayama prefecture).  In the early period,  the 
Tuberculosis Control Law required all citizens aged 
16 or over to have a chest x-ray annually.  The lung 
cancer screening program,  which was conducted in 
the late period,  was performed on individuals aged 
40 or over as legislated by the Health and Medical 
Services Law for the Aged.  Only the national health 
insurance holders or family members of the 
employment-related health insurance holders 
underwent screening in this program,  since the 
Employment-related health insurance holders were 
assigned to be screened by their companies using a 
different system.  As an annual chest x-ray 
examination,  70 × 70 mm miniature photoﬂ uorography 
with a tube voltage of 100 kV was used in the early 
period and a 100 × 100 mm miniature photoﬂ uo-
rography with tube voltage of 140 kV was used in the 
late period.  The smoking habits of all participants 
were recorded.  Sputum cytology with Saccomanno’s 
3-day pooled method was performed for individuals in 
the high-risk group,  which included individuals aged 
50 or over with a smoking index (average number of 
cigarettes smoked per day multiplied by the number 
of years smoked) of at least 600.  For the individuals 
who were suspected to have lung cancer by chest 
x-ray or sputum cytology,  further examinations were 
performed as soon as possible to conﬁ rm the 
diagnosis.
　　Data on diagnosis,  clinical stage,  therapy,  and 
survival were obtained from hospital records and/or 
data in the Okayama Cancer Registry.  Histologic 
types were classiﬁ ed according to the World Health 
Organization histologic classiﬁ cation [12].  The 
clinical stage of lung cancer was determined on the 
basis of the American Joint Committee on Cancer 
classiﬁ cations [13].
　　Categorical variables were compared using the X2 
test.  Survival rates were calculated by the Kaplan-
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Meier method.  We assessed the prognostic 
signiﬁ cance of lung cancer screening by univariate 
analysis using a log-rank test and multivariate 
analysis using Cox’s proportional hazards model. 
The variables analyzed in this study were age (ｧ 70 
years vs. ＜ 70 years),  sex,  histology (adenocarcinoma 
vs.  non-adenocarcinoma),  clinical stage (I vs.  II,  III, 
IV),  and era (1976ﾝ1984 vs.  1989ﾝ1997),  and 
hazard ratios and their 95ｵ conﬁ dence intervals 
were estimated.  Statistical analysis was performed 
using SPSS Software (SPSS Inc,  Chicago,  IL, 
USA).  A p value of 0.05 was considered statistically 
signiﬁ cant.
Results
　　The characteristics of the patients are shown in 
Table 1.  Two hundred seventy-six patients with lung 
cancer were identiﬁ ed in the early period and 541 
patients were identiﬁ ed in the late period.  Patients 
identiﬁ ed in the early period were younger on 
average than those in the late period,  which might be 
due to the diﬀ erence in the age limitation of the 
accrued subjects in each cohort.  Similarly,  the 
proportion of adenocarcinoma or clinical stage I was 
slightly lower and that of squamous cell carcinoma or 
stage IV was higher in the early period.  However, 
these diﬀ erences were not statistically signiﬁ cant.
　　Survival curves according to screening period are 
shown in Fig.  1.  Median survival time (MST) and 
5-year survival rate (5-yr) in the late period were 
49.8 months and 47.8ｵ,  respectively,  which were 
signiﬁ cantly better than those (MST : 27.8 months 
and 5-yr : 34.8ｵ) in the early period (p ＝ 0.0054). 
Regardless of clinical stage,  survival rates in the 
late period were better than those in the early 
period.  However,  a statistically signiﬁ cant diﬀ erence 
was obtained only in patients with stage IV disease 
(Table 2,  p ＝ 0.0423).  Survival curves according to 
treatment modality are shown in Fig.  2.  Signiﬁ cant 
improvement in the late period was obtained in 
patients receiving chemotherapy (MST : 13.2 months 
late vs.  10.2 months early,  p ＝ 0.0035),  but no 
diﬀ erence was shown in patients undergoing surgical 
resection (MST : not calculated,  5-year survival 
rate : 51.4ｵ late vs.  65.0ｵ early,  p ＝ 0.1403), 
radiotherapy (MST : 15.2 months late vs.  16.0 
months early,  p ＝ 0.6452) or supportive care alone 
(MST : 13.7 months late vs.  16.0 months early, 
p ＝ 0.4293).
　　One hundred seventy-three (62.7ｵ) of 276 
patients underwent surgical resection in the early 
period compared to 378 (69.9ｵ) of 541 patients in 
the late period.  The resection rate in the late period 
was signiﬁ cantly higher than that in the early period 
(p ＝ 0.038).  There was no signiﬁ cant diﬀ erence in 
the resection rate based on histology.  Among 
patients undergoing resection,  the proportion of the 
pathological stage I patients in the late period 
(230/541 : 60.8ｵ) was signiﬁ cantly higher than that 
in the early period (95/173 : 54.9ｵ,  p ＝ 0.005). 
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Table 1　　Characteristics of patients with lung cancer detected 
by population-based screening
Early period
1976ﾝ1984
Late period
1989ﾝ1997
No.  evaluated 276 541
Median age (range) 64 (34ﾝ81) 69 (35ﾝ91)
Sex : 　　 male 185 (67%) 371 (69%)
female 91 170
Histology : 
adenocarcinoma 155 (56%) 327 (60%)
squamous cell ca.  86 (31%) 141 (26%)
small cell ca.  28 (10%)  53 (10%)
others  7 ( 3%)  20 ( 4%)
Stage : 　 I 156 (57%) 338 (62%)
II  45 (16%)  43 ( 8%)
IIIA  25 ( 9%)  84 (16%)
IIIB  12 ( 4%)  29 ( 5%)
IV  38 (14%)  47 ( 9%)
Early period
Late period
Years from detection
%
 S
ur
vi
vi
ng
Fig. 1　　Survival curves of lung cancer patients according to era 
detected by lung cancer screening (276 patients in the early period 
vs.  541 patients in the late period).  Kaplan-Meier method.
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However,  the 5-year survival rate in pathological 
stage I patients did not diﬀ er between the 2 periods 
(77.4ｵ vs.  78.1ｵ,  p ＝ 0.3532,  Fig.  3).
　　We also investigated the eﬀ ect of time diﬀ erence 
of screening on survival by uni- and multi-variate 
analyses.  On univariate analysis,  the late era as well 
as younger age ( ＜ 70 years old),  female gender, 
adenocarcinoma histology,  and clinical stage I were 
signiﬁ cantly associated with better prognosis (Table 
3).  Multivariate analysis using Cox’s proportional 
hazard model also showed that the clinical stage was 
the most signiﬁ cant variable and that age was the 
second most signiﬁ cant.  As well,  the screening time 
period was also conﬁ rmed as a signiﬁ cant prognostic 
factor (hazard ratio ＝ 0.685,  95ｵ confidence 
interval : 0.563ﾝ0.832,  p ＝ 0.0002 ; Table 4).
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Table 2　　Survival of patients with lung cancer according to clinical stage
Stage Early period (1976 ﾝ 1984) Late period (1989 ﾝ 1997)No.  of patients MST (mo) No.  of patients MST (mo) p-value
I 156 (57%) not calculated 338 (63%) not calculated 0.3532
II  45 (16%) 17.3 43 (8%) 29.6 0.1277
IIIA 25 (9%) 14.8  84 (16%) 21.7 0.2286
IIIB 12 (4%) 10.3 29 (5%) 13.8 0.1149
IV  38 (14%)  5.8 47 (9%)  8.6 0.0423
A Resection
B Chemotherapy
C Radiotherapy
D Supportive therapy alone
Years Years
Years Years
%
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ur
vi
vi
ng
%
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vi
ng
%
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ng
%
 S
ur
vi
vi
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Fig. 2　　Survival curves of lung cancer patients according to era (early period vs.  late period).  Kaplan-Meier Method : thick line,  late 
period ; thin line,  early period.
A,  Survival curves according to resection (173 patients vs.  378 patients) ; B,  Survival curves according to chemotherapy (65 patients 
vs.  70 patients) ; C,  Survival curves according to radiotherapy (18 patients vs.  36 patients) ; D,  Survival curves according to support-
ive therapy alone (20 patients vs.  57 patients).
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Discussion
　　In order to confirm the recent 
improvement in lung cancer screening,  we 
designed the present study and found that 
the survival of patients detected in the 
late period was signiﬁ cantly better than 
that in the early period,  though 
statistically significant differences 
between time periods in clinical 
characteristics,  such as histology and 
stage,  were not observed.  There are 
several possible explanations for the 
statistically signiﬁ cant survival beneﬁ t 
obtained in the late period.
　　First,  more patients with an earlier 
stage of lung cancer,  even though 
technically within the same stage,  may 
have been detected in the late period.  The detection 
rates of lung cancer did not diﬀ er between the 2 
groups : 0.0470ｵ of participants screened between 
1976 and 1984 and 0.0491ｵ of those screened 
between 1989 and 1997.  However,  the resection rate 
in the late period was higher than that in the early 
period (69.9ｵ late vs.  62.7ｵ early,  p ＝ 0.038).  By 
using a larger ﬁ lm (100 × 100 mm miniature photoﬂ uo-
rography) and higher tube voltage (140 kV),  more 
information could be obtained on chest x-ray 
examination compared with the previously used 
method (70 × 70 mm miniature photoﬂ uorography 
with a tube voltage of 100 kV).  This may have 
enabled the detection of earlier lung cancer. 
Furthermore,  better training of doctors performing 
the screening and prompt examination of suspected 
cases became possible due to the Health and Medical 
Services Law for the Aged ; and this also may have 
inﬂ uenced the results.
　　Second,  the advancement of lung cancer treatment 
modalities may have improved the results of 
screening in recent years.  In the present study,  the 
survival of patients with stage II-IV disease in the 
late period was signiﬁ cantly better than that in the 
early period,  yet no improvement was shown for 
patients with stage I disease (Fig.  3).  Advancements 
in chemotherapy may have aﬀ ected these results. 
This would appear to be conﬁ rmed by the fact that 
survival improvement was obtained only in patients 
177Recent Improvement of Lung Cancer ScreeningJune 2006
Table 3　　Univariate analysis
Variables No.  ofpatients
Median survival
time (months) p-value
Era
1976ﾝ1984 276 27.8 　0.0054
1989ﾝ1997 541 49.8
Age : 
less than 70 year-old 467 ﾝ ＜ 0.0001
70 year-old or older 350 29.3
Sex : 
male 556 34.8 ＜ 0.0001
female 261 ﾝ
Histology : 
adenocarcinoma 482 60.0 ＜ 0.0001
non-adenocarcinoma 335 28.9
Clinical stage : 
stage I 494 ﾝ ＜ 0.0001
stage IIﾝIV 323 12.4
A p-stage I
B p-stage II-IV
Years
Years
%
 S
ur
vi
vi
ng
%
 S
ur
vi
vi
ng
Fig. 3　　Survival curves of lung cancer patients according to 
pathological stage (early period vs.  late period).  Kaplan-Meier 
method ; thick line,  late period ; thin line,  early period.
A,  Survival curves of patients with p-stage I disease (95 patients 
vs.  230 patients) ; B,  Survival curves of patients with p-stage IIﾝ
IV disease (71 patients vs.  99 patients).
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receiving chemotherapy (Fig.  2).  However,  the 
majority of the patients detected by mass screening 
might have had non-small cell lung cancer,  and there 
were no remarkable advancements in systemic 
chemotherapy for such cases during the period 
between the former and latter screening programs. 
Thus,  it appears to be unrealistic to assume that 
advancements in chemotherapy could be the main 
reason for the improvement in survival seen in the 
late period.
　　Third,  a recent increase in peripheral lung 
adenocarcinoma,  which can be detected by chest 
x-ray without diﬃ  culty and generally has a good 
prognosis,  may have aﬀ ected the results.  In the 
present study,  the proportion of adenocarcinoma was 
shown,  in fact,  to have increased in the late period.
　　There are several limitations in this study.  The 
current study may have a lead-time bias ; however, 
although the proportion of pathological stage I 
patients among those undergoing resection was 
signiﬁ cantly higher in the late period,  the survival of 
stage I patients did not diﬀ er between the 2 time 
periods.  This suggests that its bias might be minimal. 
As another problem,  we did not assess cost-
eﬀ ectiveness of the recent screening program ; the 
survival advantage we demonstrated was the principal 
goal of the study.  Based on these limitations,  the 
results we obtained should be cautiously interpreted.
　　In conclusion,  we found that (i) the survival of 
patients with lung cancer detected in the late period 
was signiﬁ cantly better than that of those in the 
early period ; (ii) among the patients undergoing 
resection,  the proportion of pathological stage I 
patients in the late period was signiﬁ cantly higher 
than that in the early period ; and (iii) 
multivariate analysis showed that the 
screening time period was a 
signiﬁ cant prognostic factor.  These 
observations indicate a greater 
eﬃ  cacy for the recent screening 
program than for case-control studies 
in the early period.  Furthermore,  a 
reanalysis of the Mayo Lung Project 
data,  which showed that the survival 
in the screened population was 
superior to that in the unscreened 
population [14] ,  has been 
encouraging.  Therefore,  we have to reconsider the 
eﬀ ectiveness of lung cancer screening and to continue 
studying how to improve its sensitivity and 
speciﬁ city.
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